First American Trust FSB lowered its holdings in Boston Scientific Co. (NYSE:BSX) by 25.4% in the fourth quarter, HoldingsChannel reports. The firm owned 84,604 shares of the medical equipment provider’s stock after selling 28,771 shares during the quarter. First American Trust FSB’s holdings in Boston Scientific were worth $2,990,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in BSX. West Oak Capital LLC grew its holdings in Boston Scientific by 40.0% during the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 300 shares in the last quarter. North Star Investment Management Corp. lifted its position in shares of Boston Scientific by 111.1% during the 4th quarter. North Star Investment Management Corp. now owns 2,280 shares of the medical equipment provider’s stock worth $81,000 after buying an additional 1,200 shares during the last quarter. Moody National Bank Trust Division purchased a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $108,000. Capital Guardian Trust Co. purchased a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $110,000. Finally, NumerixS Investment Technologies Inc lifted its position in shares of Boston Scientific by 1,650.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,500 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 3,300 shares during the last quarter. Hedge funds and other institutional investors own 90.72% of the company’s stock.
Several analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $43.00 price objective on shares of Boston Scientific in a research report on Tuesday. Zacks Investment Research cut shares of Boston Scientific from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Oppenheimer set a $38.00 price target on shares of Boston Scientific and gave the stock a “hold” rating in a research note on Wednesday, October 24th. BTIG Research reaffirmed a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a research note on Thursday, October 25th. Finally, Stephens reaffirmed a “market perform” rating and set a $40.00 price target on shares of Boston Scientific in a research note on Monday, November 19th. Three research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $40.12.
NYSE BSX traded down $0.39 during trading hours on Friday, reaching $35.56. The company’s stock had a trading volume of 5,488,648 shares, compared to its average volume of 6,991,511. The stock has a market cap of $49.65 billion, a price-to-earnings ratio of 28.22, a PEG ratio of 2.08 and a beta of 0.72. Boston Scientific Co. has a fifty-two week low of $25.04 and a fifty-two week high of $39.44. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 EPS for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.01. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. The firm’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.31 EPS. As a group, research analysts expect that Boston Scientific Co. will post 1.39 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “First American Trust FSB Reduces Position in Boston Scientific Co. (BSX)” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://dakotafinancialnews.com/2019/01/11/first-american-trust-fsb-reduces-position-in-boston-scientific-co-bsx.html.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: What is a stock buyback?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.